Inherited disorders of the optic nerve, including glaucoma and optic neuropathy, are important causes of blindness in children and adults. The inherited optic neuropathies most frequently encountered clinically are Leber’s hereditary optic neuropathy (LHON) and autosomal dominant (or Kjer) optic neuropathy (Neuhann and Rautenstrauss 2013).

Glaucoma is a complex disorder that includes neurodegeneration of the optic nerve as a defining clinical feature. Elevated intraocular pressure (IOP) is an important risk factor for glaucomatous optic nerve degeneration, however, ~33% of affected individuals have normal tension glaucoma (NTG) defined by progressive retinal ganglion cell loss despite IOP measurements in the normal range (<21 mmHg) (Fan and Wiggs 2010). Phenotypically, NTG can share clinical features with the inherited optic neuropathies. Glaucoma with onset before age 40 (early-onset) can be inherited as Mendelian autosomal recessive or autosomal dominant traits, whereas adult onset disease has complex inheritance (Wang and Wiggs 2014).

Current knowledge of the genetics of optic neuropathy and glaucoma makes it possible to test for mutations in disease-causing genes allowing for presymptomatic testing and risk assessment. Recent advances have revealed important disease mechanisms that may suggest potential therapeutic targets. In this perspective, we review the current recommendations, approaches, and limitations of genetic testing for these disorders and provide an update on the development of gene-based therapies.
GENETIC TESTING FOR GLAUCOMA

For many glaucoma patients reducing IOP through medical or surgical treatment can slow disease progression. Genetic testing can identify patients at risk for glaucoma so that presymptomatic surveillance and treatment plans can be developed. Currently, glaucoma genetic testing is most beneficial for patients with disease onset before age 40 (early-onset glaucoma). Mutations causing early-onset glaucoma are rare and have large biological effects, whereas DNA variants contributing to adult-onset glaucoma are common and individually have small effects (Fig. 1). Types of early-onset glaucoma caused by rare mutations with large effects are congenital glaucoma, developmental glaucoma, juvenile open-angle glaucoma, and familial normal tension glaucoma. Common variants with small individual effect sizes contribute to adult-onset primary open angle glaucoma, angle closure glaucoma, and exfoliation glaucoma.

Early-Onset Glaucoma Genetic Testing

Eight genes are currently known to cause early-onset (before age 40) glaucoma with autosomal recessive (AR) or autosomal dominant (AD) inheritance (Wang and Wiggs 2014). Approximately 20% of patients ascertained with early-onset glaucoma through tertiary care facilities will have mutations in one of the genes known to cause early-onset glaucoma (Fig. 2) (Sena et al. 2004; Lim et al. 2013). Of these, mutations in FOXC1 are most common followed by MYOC, CYP1B1, PAX6, and PITX2. Mutations are rarely identified in OPTN, TBK1 or LTBP2, even in the tertiary care setting (Hauser et al. 2006; Huang et al. 2014; Ritch et al. 2014). Although the overall clinical sensitivity for genetic testing for this group of genes is ~20%, testing for disease-causing mutations in patients and family members has several important benefits including: informed genetic counseling; presymptomatic risk assessment; and development of appropriate treatment and surveillance plans. Each of these will be discussed in the sections below.

Informed Genetic Counseling

Mutations in early-onset glaucoma genes can cause AD or AR disease: CYP1B1 and LTBP2 cause AR disease, whereas mutations in FOXC1, PITX2, PAX6, MYOC, and OPTN all cause glaucoma inherited as a dominant trait (Wang and Wiggs 2014). Phenotypically, disease caused by mutations in these genes can have similar clinical features making it difficult to make a genetic diagnosis by clinical examination alone. For example, patients with CYP1B1 mutations can present with severe glaucoma that develops during the first three years of life (congenital glaucoma); however, recent studies have shown that some CYP1B1 mutations cause disease that is not clinically evident until the second decade of life (juvenile glaucoma) (Abu-Amero et al. 2013; Millá et al. 2013).
CYP1B1-related juvenile glaucoma is inherited as a recessive trait and clinically may not be distinguished from dominantly inherited juvenile or developmental glaucoma caused by mutations in MYOC, FOXC1, PITX2, or PAX6. Establishing the molecular diagnosis for these patients will clarify the inheritance pattern making informed genetic counseling and risk assessment possible.

Mutations in both LTBP2 and CYP1B1 can cause autosomal recessive congenital glaucoma (onset before the age of 3). In the United States, the incidence of congenital glaucoma is estimated to be approximately 1/10,000 (Fung et al. 2013). CYP1B1 mutations are found in ~20% of patients, whereas LTBP2 mutations are very rare (Lim et al. 2013). Interestingly, in the United States the CYP1B1 mutation carrier frequency is three to five times higher than the incidence of congenital glaucoma would predict using Hardy-Weinberg distribution (Wiggs et al. 2014). The most prevalent CYP1B1 mutations in the United States carriers are missense alleles which may contribute to less severe early-onset disease (Wiggs et al. 2014). These results suggest that CYP1B1-related glaucoma may be more common than expected and that patients with juvenile and developmental glaucoma should be tested for CYP1B1 mutations, in addition to patients with severe congenital glaucoma.

Presymptomatic Risk Assessment

A family history of glaucoma is an important risk factor for disease development (Kooner et al. 2014), however, risk assessment based on family history alone is not precise. Genetic testing makes it possible to accurately identify mutation carriers with significantly increased risk for disease because of the high penetrance of mutations in early-onset glaucoma genes. The identification of individuals at risk for glaucoma makes it possible to begin treatment before the onset of irreversible optic nerve disease, thus providing the best opportunity to maintain useful sight.

Surveillance and Treatment Plans

For patients identified as early-onset glaucoma mutation carriers, defining the molecular diagnosis can impact therapeutic decisions. For ex-
ample, several MYOC mutations (Pro370Leu, Tyr437His) (Liu and Vollrath 2004) cause severe early-onset disease that usually requires surgery for treatment, whereas the most common MYOC mutation (GLN368X) can cause much milder disease that can be managed with topical medications (Allingham et al. 1998; Hogewind et al. 2010). Patients with less severe MYOC mutations can have earlier onset of disease if they also carry common modifying variants in \( \text{COL15A1} \) and \( \text{COL18A1} \) (Wiggs et al. 2013), suggesting that testing should be performed for both the primary mutations as well as modifier alleles.

Additionally, several early-onset glaucoma gene mutations can also cause systemic manifestations requiring further clinical attention. Patients with early-onset glaucoma related to Aniridia caused by deletion of \( \text{PAX6} \) may also be at risk for Wilm’s tumor and should have a screening renal ultrasound (Hingorani et al. 2012). Patients with mutations in \( \text{FOXC1} \) or \( \text{PITX2} \) can also have cardiac abnormalities (Gripp et al. 2013; Wang et al. 2013) and hearing loss (D’haene et al. 2011).

**GENETIC TESTING FOR ADULT-ONSET GLAUCOMA**

Nine genes have been statistically associated with adult-onset glaucoma (disease onset after the age of 40) (Wang and Wiggs 2014). Although these associations are robust, genetic testing for adult-onset disease has several challenges. First, individual variants have a small effect on the overall disease risk and likely do not have a significant clinical impact unless they are in the context of other genetic and/or environmental risk factors. Second, the variants currently associated with adult onset disease are common and although the distribution among affected and unaffected individuals is significant, individually the sensitivity and specificity is not sufficient for a clinically useful test. For example, variants in the \( \text{LOXL1} \) genomic region are significantly associated with pseudoexfoliation glaucoma and are found in \( \sim 99\% \) of affected patients, however, they are also found in 60%–80% of unaffected individuals (Fan et al. 2011). The development of gene panels, single nucleotide polymorphism (SNP) scores, and combinations of gene and environmental risk factors may yield useful gene-based tests for adult-onset glaucomas, however, these tests need to be validated in the clinical setting and should be correlated with clinical outcomes.

**CURRENT RECOMMENDATIONS FOR GLAUCOMA GENETIC TESTING**

Genetic testing is clinically useful for glaucoma patients with disease onset before age 40. Up to 20% of these patients will have a mutation in one of the genes currently known to cause early-onset disease. This recommendation is consistent with the policy advocated by the Genetic Testing Task Force for the American Academy of Ophthalmology (Stone et al. 2012). If a mutation in the affected patient is found, further testing of members can be performed. In one study of Australian patients, testing of individuals with a family history of glaucoma and with onset up to age 50 was useful if the disease was advanced (Souzeau et al. 2013). Testing for patients with onset after age 50 is not currently useful clinically, but as more genetic and environmental risk factors are discovered comprehensive risk panel tests can be developed and validated.

**GENETIC TESTING FOR PRIMARY OPTIC NEUROPATHY**

Approximately 30%–50% of patients with primary optic atrophy will have mutations in \( \text{OPA1} \) or mitochondrial DNA (LHON) (Fig. 3) (Yu-Wai-Man et al. 2011). \( \text{OPA1} \) mutations cause dominantly inherited optic atrophy that usually is bilateral and develops during the first or second decade of life. Three point mutations in the mitochondrial ND4 gene are responsible for \( \sim 90\% \) of LHON (Mackey et al. 1996). These mutations are maternally inherited and can have an asymmetric presentation. The mitochondrial DNA haplogroup appears to contribute to disease pathogenicity with haplogroup J of particular importance (Howell et al. 2003; Sadun et al. 2004). Rarely, mutations in \( \text{OPA3} \)
cause recessive optic atrophy that is commonly associated with cataracts and other neurological abnormalities (Ferre´ et al. 2009). Genetic testing for mutations in OPA1, OPA3, and mitochondrial DNA has important benefits for patients and family members including informed genetic counseling and risk assessment, avoidance of environmental exposures that may contribute to disease severity and identification of individuals who could be eligible for emerging gene-based clinical therapy.

Avoidance of Environmental Risk Factors
Studies have suggested that patients with mitochondrial DNA mutations causing LHON may have worse disease if exposed to excessive alcohol consumption, smoking, or have poor nutrition (Sadun et al. 2003; Kirkman et al. 2009). Patients carrying disease-causing mitochondrial DNA mutations may benefit from avoiding these risk factors. Additionally, there is some evidence to suggest that males with LHON may develop more severe disease than females owing to a putative protective effect of the X chromosome (Shankar et al. 2008).

Identify Individuals with Mitochondrial DNA Mutations Who May be Eligible for Gene-Based Clinical Therapy
Patients with selected mitochondrial DNA mutations may be eligible for gene-based therapies. A clinical trial evaluating the safety of adeno-associated virus (AAV) delivery of mitochondrial DNA to patients with Leber’s hereditary optic atrophy is underway (Cwerman-Thibault et al. 2014; Koilkonda et al. 2014; Lam et al. 2014). Future gene-based therapies may be available for patients with mitochondrial DNA mutations as well as other genetic forms of primary optic atrophy.

Figure 3. Distribution of mutation in mitochondrial DNA or OPA1 in a cohort of primary optic atrophy patients. Mutations in mitochondrial DNA or OPA1 are presented as a fraction of 64 patients evaluated through the genetic testing service at the Massachusetts Eye and Ear Infirmary. Fifty-six percent of patients with primary optic atrophy do not have a mutation in mitochondrial DNA, OPA1, or OPA3.
Approaches to Genetic Testing for Optic Atrophy (Glaucoma and Primary Optic Neuropathy)

The group of genes currently known to cause early-onset glaucoma and primary optic atrophy could be tested by sequentially screening individual genes, however, because of the extensive phenotypic overlap among these conditions a panel test that simultaneously tests for mutations in all known genes is preferred. Because the primary open angle glaucoma normal-tension subgroup can have a clinical presentation similar to patients with primary optic atrophy, it is useful to include OPA1, OPA3, and the mitochondrial genome as well as the eight genes known to cause early-onset forms of glaucoma in the test. Panel testing can be accomplished using selective exon capture for all coding/genomic regions of interest followed by next generation sequencing. A streamlined bioinformatic analysis is necessary to rapidly identify disease-causing mutations. Bioinformatic approaches are also required to identify the mitochondrial DNA heteroplasmy as well as the underlying mitochondrial DNA haplogroup that can impact the disease pathogenicity (Bannwarth et al. 2013). Another benefit of the gene panel approach is the opportunity to discover combinations of disease-causing mutations that may be overlooked using sequential screening.

Evaluation of copy number variation (CNVs, large genomic deletions and duplications) is necessary for comprehensive genetic testing. For the glaucoma and optic atrophy genes, genomic deletions and duplications, which would not be identified by DNA sequencing methods, are known to cause disease. In particular, both deletions and duplications of FOXC1 and OPA1 are relatively common disease-causing mutations (Chanda et al. 2008; Führmann et al. 2009; Almind et al. 2011). Deletions and duplications may also impact regulatory elements that would not be targeted as part of the sequencing approaches (McBride et al. 2011; Volkmann et al. 2011). CNVs can be detected using a variety of approaches, including MLPA (Multiplex ligation-dependent probe amplification) (Redeker et al. 2008), array CGH (array Comparative Genomic Hybridization) (Delahaye et al. 2012), and quantitative PCR (Wang et al. 2001).

Limitations for Genetic Testing for Optic Neuropathies (Early-Onset Glaucoma and Primary Optic Atrophy)

The low clinical sensitivity is a major limitation of current genetic testing for early-onset glaucoma and primary optic atrophy (20% and 50%, respectively). The discovery of more disease-causing genes will improve the overall sensitivity of genetic testing for these disorders. Recent advances in genomic technologies, including whole exome and whole genome sequencing are making it possible to efficiently identify novel disease genes.

Another important limitation is the lack of clinical correlations and outcomes for disease-related mutations and variants. Early-onset glucoma and primary optic atrophy can show considerable variable expressivity, both within and among affected families, which can complicate the clinical utility of the genetic diagnostic test. More research is needed to understand the molecular events that contribute to the spectrum of disease caused by early-onset glaucoma and primary optic atrophy genes.

For adult-onset glaucomas, clinical correlations and outcomes associated with specific genetic variants are also lacking. More complete risk panels (including both genetic and environmental factors) need to be developed and tested for disease risk prediction. Additionally, for adult-onset disease, specific risk factors could be correlated with selected clinical features such as IOP level, optic nerve disease susceptibility, and other glaucoma-related clinical features such as thin central corneal thickness.

Opportunities for Novel Therapies

The identification of disease-causing genes is an important first step toward the development of gene-based therapies, which may involve gene replacement, gene inactivation or may use small molecules or other chemicals to modulate the mutation pathogenicity. Some opportunities...
for gene-based therapies for selected early-onset glaucoma and optic neuropathy genes are discussed in the following sections.

**MYOC**

Compelling evidence suggests that MYOC mutations cause a misfolded protein response that leads to endoplasmic reticulum stress and subsequent cellular dysfunction (Anholt and Carbone 2013). Interestingly, sodium phenylbutrate, a small molecule known to modulate the misfolded protein response can reduce IOP in a transgenic mouse with the MYOC mutation (Zode et al. 2011, 2012). This result supports the hypothesis that the misfolded protein response contributes to disease development and suggests that treatment approaches could involve reducing MYOC expression, inactivating the mutant mRNA using siRNA or other approaches such as CRISPR.

**CYP1B1**

Loss of CYP1B1 function results in early onset glaucoma. Patients with CYP1B1-related disease can show variable expressivity resulting in a range of disease phenotypes extending from severe congenital glaucoma to disease onset in later teenage years (Suri et al. 2009). In general, null alleles cause the most severe disease, whereas missense alleles can result in milder disease with later onset (López-Garrido et al. 2013). Phenotypically, CYP1B1-related glaucoma is caused, at least in part, by abnormal development of critical structures in the ocular anterior segment (Hollander et al. 2006). However, in patients with later onset disease ocular development may not be severely impaired and other processes related to reduced protein activity may be responsible for disease. For these patients, gene-based therapies could restore sufficient protein function that glaucoma development could be delayed and even eliminated.

**ND4 Leber’s Hereditary Optic Neuropathy (LHON)**

More than 90% of patients affected by LHON have a point mutation in the mitochondrial ND4 gene that codes for a critical subunit of respiratory chain complex I (Farrar et al. 2013). A gene-based treatment trial is currently in progress to test the safety and efficacy of delivery of a nuclear ND4 gene that could restore this critical protein to impaired mitochondria (Cwerman-Thibault et al. 2014; Lam et al. 2014). Mitochondrial defects may also be a factor in the development of adult-onset glaucoma (Jeoung et al. 2014) and the development of mitochondrial DNA therapies could potentially be beneficial for selected glaucoma patients. Additionally, gene-based therapies could be targeted in the future to other mitochondrial DNA mutations affecting other genes can also cause and/or contribute to optic neuropathies.

**Neuroprotective Therapies**

Therapies capable of protecting or repairing optic nerve function will provide the best opportunities to maintain and preserve sight in patients affected with inherited optic neuropathies. Genes associated with common forms of glaucoma, and especially the subgroup of primary open angle glaucoma with optic nerve degeneration without elevation of IOP (normal-tension glaucoma) could be targets for gene-based neuroprotective therapies. For example, CDKN2BAS has been associated with primary open angle glaucoma (POAG), normal-tension glaucoma (NTG), and optic nerve CDR (Wiggs et al. 2012). This gene codes for an antisense RNA that regulates the expression of other proteins involved in cell cycle progression. The robust association between CDKN2BAS variants and optic nerve disease in glaucoma suggests that modulating CDKN2BAS expression, perhaps through a gene-based approach, could be neuroprotective.

Cell-based therapies, particularly the use of glial cells and mesenchymal stem cells, could protect against neurodegeneration and may also be capable of repairing optic nerve damage (Johnson and Martin 2013). Stem cells produce a variety of nerve growth factors that may have the ability to preserve and repair ganglion cell function. A clinical trial evaluating delivery of ciliary neurotrophic factor (CNTF), a
nerve growth factor that may have neuroprotective effects in glaucoma (Pease et al. 2009; Johnson et al. 2011), is currently ongoing (NCT014 08472). The results of these and other studies could lead to the development of novel therapies capable of preventing optic nerve degeneration in both glaucoma and primary optic atrophy.

CONCLUDING REMARKS

Glaucoma and primary optic atrophy are the most common inherited optic neuropathies encountered in a clinical setting and are important causes of blindness throughout the world. Genetic studies have revealed important genes responsible for these conditions and genetic testing for mutations in known genes can be beneficial. For early-onset glaucoma, genetic testing is most useful for patients with disease onset before age 40. The overall clinical sensitivity of genetic testing for both early-onset glaucoma and primary optic atrophy will improve as new genes responsible for these conditions are discovered. For some optic nerve disorders, genetic information is defining approaches to novel gene-based therapies. Cell-based therapies and replacement of neurotrophic factors may also lead to novel neuroprotective treatment.

REFERENCES

‘Reference is also in this subject collection.


Cite this article as *Cold Spring Harbor Perspect Med* 2015;5:a017277


# Genetics of Primary Inherited Disorders of the Optic Nerve: Clinical Applications

Keri F. Allen, Eric D. Gaier and Janey L. Wiggs

*Cold Spring Harb Perspect Med* 2015; doi: 10.1101/cshperspect.a017277

<table>
<thead>
<tr>
<th>Subject Collection</th>
<th>Retinal Disorders: Genetic Approaches to Diagnosis and Treatment</th>
</tr>
</thead>
</table>
  Naveen Mysore, Jamie Koenekoop, Shen Li, et al.  
  Luk H. Vandenberghe |
| Genes and Mutations Causing Autosomal Dominant Retinitis Pigmentosa | The Status of *RPE65* Gene Therapy Trials: Safety and Efficacy  
  Stephen P. Daiger, Sara J. Bowne and Lori S. Sullivan  
  Eric A. Pierce and Jean Bennett |
| RNA-Seq: Improving Our Understanding of Retinal Biology and Disease | Convergence of Human Genetics and Animal Studies: Gene Therapy for X-Linked Retinoschisis  
  Michael H. Farkas, Elizabeth D. Au, Maria E. Sousa, et al.  
  Ronald A. Bush, Lisa L. Wei and Paul A. Sieving |
| Differential Gene Expression in Age-Related Macular Degeneration | Gene Therapies for Neovascular Age-Related Macular Degeneration  
  Denise J. Morgan and Margaret M. DeAngelis  
  Peter Pechan, Samuel Wadsworth and Abraham Scaria |
| Genetics of Primary Inherited Disorders of the Optic Nerve: Clinical Applications | Gene Therapy for the Retinal Degeneration of Usher Syndrome Caused by Mutations in *MYO7A*  
  Keri F. Allen, Eric D. Gaier and Janey L. Wiggs  
  Vanda S. Lopes and David S. Williams |
| Genetic Modifiers and Oligogenic Inheritance | Gene Therapy of *ABCA4*-Associated Diseases  
  Maria Kousi and Nicholas Katsanis  
  Alberto Auricchio, Ivana Trapani and Rando Allikmets |
| Stem Cells as Tools for Studying the Genetics of Inherited Retinal Degenerations | Gene Therapy Using Stem Cells  
| Leber Congenital Amaurosis Caused by Mutations in *RPGRIP1* | Gene Therapy for Choroideremia Using an Adeno-Associated Viral (AAV) Vector  
  Tiansen Li  
  Alun R. Barnard, Markus Groppe and Robert E. MacLaren |

For additional articles in this collection, see [http://perspectivesinmedicine.cshlp.org/cgi/collection/](http://perspectivesinmedicine.cshlp.org/cgi/collection/)

Copyright © 2015 Cold Spring Harbor Laboratory Press; all rights reserved